Rentschler Biopharma announced a collaboration on Aug. 23, 2023 with Cell and Gene Therapy Catapult (CGT Catapult), a UK-based independent innovation and technology organization specializing in cell and gene therapies, and Refeyn, a UK-based provider of mass photometry instruments and technologies, under which the three organization will develop and apply innovative process analytical technologies (PAT) to improve the manufacturing process for adeno-associated viruses (AAVs) in gene therapy production. Under this two-year collaboration, the partners aim to develop a digitized and automated AAV gene therapy manufacturing platform. Source: Biopharm International 29/8/2023